Data base for:

  • Conferences
  • Research funding opportunities
  • Competitions / Awards

Register for free and add any data by yourself!

Filter conferences

 
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
 
      
      
 
      
 
      
      
      
      
      
      
      
      
      
      
Oncolytic Virotherapy Summit

Oncolytic Virotherapy Summit

Categories

Date of beginning

Tuesday, 03 December 2019

Duration

3 days

City

Boston, Massachusetts

Country

United States

Contact

Kaltrina Kastrati

E-Mail

This email address is being protected from spambots. You need JavaScript enabled to view it.

Memo

The Oncolytic Virotherapy Summit is back for its fifth year as the only conference to bring together industry leaders, clinicians and academic experts focused on finding an effective immuno-oncology. Over 3 days packed with compelling case studies, diverse panels and varied networking opportunities, you'll glean insights from industry and academic leaders. The 2019 agenda will reflect the strides taken by the community over the past year as well as forming the future of oncolytic virus development. Tickets: https://go.evvnt.com/501063-1?pid=5569  Date and Time: On Tuesday December 03, 2019 at 8:00 am ends Thursday December 05, 2019 at 4:00 pm Venue details: The Westin Boston Waterfront, 425 Summer Street, Boston, Massachusetts, 02210, United States Prices:Conference Only : USD 2399.0,Conference + 1 Workshop: USD 2999.0,Conference + 2 Workshops: USD 3399.0 Speakers: Lance Weed, Vice President Operations, uniQure, Anton Xavier, Founder, K9 Biotech, Michael Wood MBA, Founder and Chief Operating Officer, OncoMyx, Robert Coffin, CEO, Replimmune, Daniel Katzman, CEO, Unleash Immuno Oncolytics, Dr Erik Digman Wiklund, Chief Business Officer, Targovax ASA, Michael Moore, Vice President Investor Relations and Corporate Communications, Oncolytics Biotech, David Sherris, President and Chief Executive Officer, GenAdam Therapeutics Inc., Louis Cantolupo, Chief Operating Officer, Unleash Immuno Oncolytics, Christophe Quéva, Chief Scientific Officer, Oncorus, Sridhar Pennathur, Senior Director and Fellow Biopharmaceutical Development, AstraZeneca, Dr John Goldberg, Senior Vice President Clinical Development and Practicing Paediatric Oncologist, Oncorus, Brian Haines PhD, Senior Director Pharmacology and Toxicology, Oncorus, Lorena Lerner, Vice President Molecular Biology and Virology, Oncorus, Beatriz Mesa, Senior Director Oncolytic Virus Manufacturing, Sorrento Therapeutics, Steve Thorne, Chief Scientific Officer, Western Oncolytics, Shara Dellatore, Principal Scientist and Group Leader, Merck, Angelica Loskog, CEO, Lokon Pharma, Maritza McIntyre, Former Chief Gene Therapy Branch, FDA